Or they might be working for GlaxoSmithKline. If GSK can delay implementation of HPV vaccination policies until Cervarix hits the market, they've substantially reduced Merck's lead in the HPV race.
Possibly, but they don't strike me as smart enough.
Maybe that's part of their plan!?